Combination therapy of IFN-β/MSCs advantageously does not require immunosuppression and directly controls melanoma proliferation, allowing it to function as an anti-tumor therapy (Studeny et al., 2002; Du et al., 2019; Heo et al., 2019; Serakinci and Cagsin, 2019; Serhal et al., 2019). The gene discussed is IFNB1; the disease is neoplasm.